Airbus Joins Air India A320 Altitude Drop Probe 
Japan Posts First Current Account Deficit in 17 Months as Dividend Payments Surge 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
Australian Shares Fall as Westpac Slides, Miners Gain Ahead of RBA Decision 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
AstraZeneca Q2 Earnings Beat Forecasts as Oncology Growth Supports 2026 Outlook 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Japan Executives Warn Weak Yen and Currency Volatility Threaten Economy 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
New Mexico Measles Outbreak Cost Reached $5.4 Million, Study Finds 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
South Korea's SK Chemicals has partnered with AstraZeneca's Korean affiliate in a contract manufacturing organization (CMO) agreement. SK Chemicals will produce and globally distribute Sidapvia, a new treatment for type 2 diabetes, combining leading active ingredients dapagliflozin and sitagliptin.
Under this agreement, SK Chemicals will be responsible for the manufacturing and global distribution of Sidapvia, a groundbreaking combination of Forxig (dapagliflozin) and sitagliptin. Sidapvia is indicated for adults aged 18 and older with type 2 diabetes, a condition characterized by improper insulin function and high blood sugar levels.
SK Chemicals and AstraZeneca have jointly developed this promising diabetes treatment. While SK Chemicals focuses on manufacturing and distribution, AstraZeneca will be the marketing authorization holder (MAH). They will handle country-specific licensing and marketing efforts, and South Korea has already granted licensing for Sidapvia, making it the first country to do so.
Sidapvia combines two active ingredients, Forxiga and sitagliptin, globally recognized as a leading SGLT-2 inhibitor and top-selling DPP-4 inhibitor. These ingredients work through different mechanisms of action to effectively lower blood glucose levels, offering a viable option for managing complications among diabetic patients.
Ahn Jae-hyun, the CEO of SK Chemicals, expressed utmost confidence in the company's pharmaceutical technology and production capabilities. These capabilities have paved the way for the supply of medicines to numerous countries, and Ahn emphasized the company's plans to foster diverse collaboration opportunities.
The collaboration between SK Chemicals and AstraZeneca began in early 2020, with AstraZeneca providing SK Chemicals with active pharmaceutical ingredients (APIs) and funding research for diabetes treatment development. Subsequently, SK Chemicals took over product research and development and conducted domestic clinical trials. With this new agreement as a starting point, SK Chemicals aims to expand the supply of Sidapvia in Korea and the global market.
This collaboration marks a significant milestone for SK Chemicals and AstraZeneca, solidifying their commitment to advancing diabetes treatment and improving the lives of millions of patients worldwide.
